Fate Therapeutics Q1 Revenue $1.3M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Reports Q1 revenue $1.3M, consensus $1.55M. "We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational clinical trial of FT819 for the treatment of lupus nephritis to provide eligible trial patients a truly accessible CAR T-cell treatment option," said Bob Valamehr, president and CEO of Fate Therapeutics. "Our acceptance into the FDA's highly competitive CDRP Program, combined with our RMAT designation, reflects a recognition of the strength of our initial Phase 1 clinical data and provides a powerful regulatory foundation as we advance FT819 along an accelerated clinical pathway. With planned clinical advancement of FT819 on multiple fronts, next generation CAR T-cell programs entering clinical trials, a strong cash balance supporting our runway into 2028 and a team that continues to execute at the highest level, we believe 2026 will be a defining year for Fate Therapeutics."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FATE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FATE
Wall Street analysts forecast FATE stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 2.840
Low
2.00
Averages
4.64
High
8.00
Current: 2.840
Low
2.00
Averages
4.64
High
8.00
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FT836 Shows Significant Lesion Reduction in Metastatic Colorectal Cancer
- Clinical Data Highlights: FT836 demonstrates significant target lesion reduction in metastatic colorectal cancer patients, with all subjects treated without conditioning chemotherapy, indicating the potential efficacy and safety of this therapy.
- Innovative Technology Application: The incorporation of Sword and Shield™ technology in FT836 eliminates the need for lymphodepleting chemotherapy, enhancing CAR T-cell persistence in the tumor microenvironment, thereby improving treatment accessibility and patient tolerability.
- Preliminary Efficacy Assessment: Among nine patients, KRAS wild-type individuals with seven prior lines of therapy exhibited significant reductions in target lesion size and a 62% decrease in CEA tumor marker, providing robust support for further research.
- Future Research Directions: Based on these preliminary results, the company plans to focus on the metastatic colorectal cancer patient population, expanding clinical trials to validate the long-term efficacy and safety of FT836.
See More
Analysis of Fate Therapeutics' Cash Burn Risks
- Stock Performance: Fate Therapeutics' stock has surged 135% over the past year, providing substantial returns for shareholders, yet this rise masks the underlying risks associated with its cash burn.
- Cash Reserves vs. Burn Rate: As of March 2026, Fate Therapeutics holds $175 million in cash with an annual cash burn of $108 million, translating to a cash runway of approximately 19 months; however, without a reduction in cash burn, the company may soon face liquidity issues.
- Revenue Decline: While Fate Therapeutics managed to reduce its cash burn by 14% over the past year, its operating revenue plummeted by 53%, indicating significant growth challenges that could hinder future fundraising efforts.
- Financing Risks: Fate Therapeutics' cash burn represents 33% of its $331 million market capitalization, suggesting that if the company needs to raise funds through share issuance, shareholders could experience considerable dilution, raising further investor concerns.
See More
GT Biopharma: Three Drugs Enter Human Trials
- Market Valuation Struggles: As of mid-May 2026, GT Biopharma's market cap stood at approximately $13 million, indicating a significant undervaluation of this clinical-stage immuno-oncology company, prompting investors to consider potential value recovery.
- Significant Clinical Progress: GT Biopharma has advanced three TriKE candidates into clinical trials, with GTB-3650 targeting treatment-resistant blood cancers, and a critical data update expected in the second half of 2026, which could influence the company's future trajectory.
- Innovative Therapeutic Platform: The company holds exclusive rights to the TriKE platform designed to activate natural killer cells to directly attack tumors, leveraging technology from the University of Minnesota, showcasing immense potential in the tumor immunotherapy space that could transform existing treatment paradigms.
- Enormous Market Opportunity: The global oncology market is projected to grow from $139 billion in 2025 to $268 billion by 2034, and if GT Biopharma's product line succeeds, it could secure a significant position in this vast market, leading to substantial commercial returns.
See More
GT Biopharma Advances Three Drug Candidates in Clinical Trials
- Market Valuation: As of May 2026, GT Biopharma's market capitalization stands at approximately $13 million, indicating significant undervaluation by the market despite having three drug candidates in human trials, suggesting a potential investment opportunity.
- Clinical Progress: The lead candidate GTB-3650, targeting treatment-resistant blood cancers, has completed patient enrollment across four dose cohorts, with early safety assessments showing no dose-limiting toxicities, and a meaningful data update is expected in the second half of 2026.
- New Drug Development: The first patient for GTB-5550 was dosed in May 2026, targeting the B7-H3 protein across multiple solid tumors, indicating a market potential significantly larger than that of the blood cancer drug, and it utilizes subcutaneous dosing for improved patient convenience.
- Market Outlook: The global oncology market is projected to grow from approximately $139 billion in 2025 to about $268 billion by 2034, positioning GT Biopharma's technology platform to potentially capture a significant share of this expansive market if successful.
See More
Fate Therapeutics Unveils CAR T-Cell Therapy Data at Major Conferences
- Clinical Data Presentation: Fate Therapeutics will present preliminary Phase 1 results of FT836 at the American Society of Clinical Oncology Annual Meeting from May 29 to June 2, 2026, aiming to overcome solid tumor escape mechanisms, potentially offering new hope for cancer treatment.
- Safety Study: The Phase 1 study of FT819 will be showcased at the European Congress of Rheumatology on June 4, 2026, emphasizing its safety and efficacy in systemic lupus erythematosus, which could promote same-day discharge treatment models.
- Dual CAR T-Cell Therapy: FT839 will be orally presented at the same conference, demonstrating its dual-targeting capability for B and T cells in autoimmune diseases without preconditioning, potentially providing more convenient treatment options for patients.
- Funding Support: This research is supported by the California Institute for Regenerative Medicine, highlighting the company's ongoing investment in regenerative medicine and commitment to innovative therapies, which may enhance its market competitiveness.
See More
Cell Therapies Propel Growth in Anti-Aging Market
- Market Growth Potential: The global cell therapy market was valued at approximately $4.7 billion in 2023 and is expected to exceed $20 billion by 2030, indicating strong interest from biotech firms and investors in cellular repair and regeneration therapies.
- Anti-Aging Therapy Progress: Avaí Bio, in collaboration with Austrianova, has completed the Master Cell Bank (MCB) of α-Klotho protein-overexpressing cells, marking a significant milestone that will advance clinical trial processes aimed at developing cell therapies for age-related diseases.
- Focus on Neurodegenerative Diseases: Analysts project the neurodegenerative disease treatment market will grow from $58.4 billion in 2025 to $85 billion by 2032, reflecting a surge in investment towards disease-modifying therapies, particularly in Alzheimer's and Parkinson's disease.
- Clinical Trial Developments: BioAge Labs' BGE-102 demonstrated significant reductions in inflammatory biomarkers in its Phase 1 trial, with plans to initiate a Phase 2 cardiovascular risk trial in the first half of 2026 to further validate its therapeutic potential.
See More
FT836 Shows Significant Lesion Reduction in Metastatic Colorectal Cancer
- Clinical Data Highlights: FT836 demonstrates significant target lesion reduction in metastatic colorectal cancer patients, with all subjects treated without conditioning chemotherapy, indicating the potential efficacy and safety of this therapy.
- Innovative Technology Application: The incorporation of Sword and Shield™ technology in FT836 eliminates the need for lymphodepleting chemotherapy, enhancing CAR T-cell persistence in the tumor microenvironment, thereby improving treatment accessibility and patient tolerability.
- Preliminary Efficacy Assessment: Among nine patients, KRAS wild-type individuals with seven prior lines of therapy exhibited significant reductions in target lesion size and a 62% decrease in CEA tumor marker, providing robust support for further research.
- Future Research Directions: Based on these preliminary results, the company plans to focus on the metastatic colorectal cancer patient population, expanding clinical trials to validate the long-term efficacy and safety of FT836.
See More
Analysis of Fate Therapeutics' Cash Burn Risks
- Stock Performance: Fate Therapeutics' stock has surged 135% over the past year, providing substantial returns for shareholders, yet this rise masks the underlying risks associated with its cash burn.
- Cash Reserves vs. Burn Rate: As of March 2026, Fate Therapeutics holds $175 million in cash with an annual cash burn of $108 million, translating to a cash runway of approximately 19 months; however, without a reduction in cash burn, the company may soon face liquidity issues.
- Revenue Decline: While Fate Therapeutics managed to reduce its cash burn by 14% over the past year, its operating revenue plummeted by 53%, indicating significant growth challenges that could hinder future fundraising efforts.
- Financing Risks: Fate Therapeutics' cash burn represents 33% of its $331 million market capitalization, suggesting that if the company needs to raise funds through share issuance, shareholders could experience considerable dilution, raising further investor concerns.
See More
GT Biopharma: Three Drugs Enter Human Trials
- Market Valuation Struggles: As of mid-May 2026, GT Biopharma's market cap stood at approximately $13 million, indicating a significant undervaluation of this clinical-stage immuno-oncology company, prompting investors to consider potential value recovery.
- Significant Clinical Progress: GT Biopharma has advanced three TriKE candidates into clinical trials, with GTB-3650 targeting treatment-resistant blood cancers, and a critical data update expected in the second half of 2026, which could influence the company's future trajectory.
- Innovative Therapeutic Platform: The company holds exclusive rights to the TriKE platform designed to activate natural killer cells to directly attack tumors, leveraging technology from the University of Minnesota, showcasing immense potential in the tumor immunotherapy space that could transform existing treatment paradigms.
- Enormous Market Opportunity: The global oncology market is projected to grow from $139 billion in 2025 to $268 billion by 2034, and if GT Biopharma's product line succeeds, it could secure a significant position in this vast market, leading to substantial commercial returns.
See More
GT Biopharma Advances Three Drug Candidates in Clinical Trials
- Market Valuation: As of May 2026, GT Biopharma's market capitalization stands at approximately $13 million, indicating significant undervaluation by the market despite having three drug candidates in human trials, suggesting a potential investment opportunity.
- Clinical Progress: The lead candidate GTB-3650, targeting treatment-resistant blood cancers, has completed patient enrollment across four dose cohorts, with early safety assessments showing no dose-limiting toxicities, and a meaningful data update is expected in the second half of 2026.
- New Drug Development: The first patient for GTB-5550 was dosed in May 2026, targeting the B7-H3 protein across multiple solid tumors, indicating a market potential significantly larger than that of the blood cancer drug, and it utilizes subcutaneous dosing for improved patient convenience.
- Market Outlook: The global oncology market is projected to grow from approximately $139 billion in 2025 to about $268 billion by 2034, positioning GT Biopharma's technology platform to potentially capture a significant share of this expansive market if successful.
See More
Fate Therapeutics Unveils CAR T-Cell Therapy Data at Major Conferences
- Clinical Data Presentation: Fate Therapeutics will present preliminary Phase 1 results of FT836 at the American Society of Clinical Oncology Annual Meeting from May 29 to June 2, 2026, aiming to overcome solid tumor escape mechanisms, potentially offering new hope for cancer treatment.
- Safety Study: The Phase 1 study of FT819 will be showcased at the European Congress of Rheumatology on June 4, 2026, emphasizing its safety and efficacy in systemic lupus erythematosus, which could promote same-day discharge treatment models.
- Dual CAR T-Cell Therapy: FT839 will be orally presented at the same conference, demonstrating its dual-targeting capability for B and T cells in autoimmune diseases without preconditioning, potentially providing more convenient treatment options for patients.
- Funding Support: This research is supported by the California Institute for Regenerative Medicine, highlighting the company's ongoing investment in regenerative medicine and commitment to innovative therapies, which may enhance its market competitiveness.
See More
Cell Therapies Propel Growth in Anti-Aging Market
- Market Growth Potential: The global cell therapy market was valued at approximately $4.7 billion in 2023 and is expected to exceed $20 billion by 2030, indicating strong interest from biotech firms and investors in cellular repair and regeneration therapies.
- Anti-Aging Therapy Progress: Avaí Bio, in collaboration with Austrianova, has completed the Master Cell Bank (MCB) of α-Klotho protein-overexpressing cells, marking a significant milestone that will advance clinical trial processes aimed at developing cell therapies for age-related diseases.
- Focus on Neurodegenerative Diseases: Analysts project the neurodegenerative disease treatment market will grow from $58.4 billion in 2025 to $85 billion by 2032, reflecting a surge in investment towards disease-modifying therapies, particularly in Alzheimer's and Parkinson's disease.
- Clinical Trial Developments: BioAge Labs' BGE-102 demonstrated significant reductions in inflammatory biomarkers in its Phase 1 trial, with plans to initiate a Phase 2 cardiovascular risk trial in the first half of 2026 to further validate its therapeutic potential.
See More
